+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Hematologic Malignancies Testing Market by Technology (Cytogenetics, Flow Cytometry, Immunohistochemistry), Application (Leukemia, Lymphoma, Multiple Myeloma), End User, Sample Type, Test Mode - Global Forecast 2025-2030- Product Image
Hematologic Malignancies Testing Market by Technology (Cytogenetics, Flow Cytometry, Immunohistochemistry), Application (Leukemia, Lymphoma, Multiple Myeloma), End User, Sample Type, Test Mode - Global Forecast 2025-2030- Product Image
Sale

Hematologic Malignancies Testing Market by Technology (Cytogenetics, Flow Cytometry, Immunohistochemistry), Application (Leukemia, Lymphoma, Multiple Myeloma), End User, Sample Type, Test Mode - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 197 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 5924675
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The Hematologic Malignancies Testing Market is evolving rapidly as healthcare organizations pursue more effective diagnostic strategies and digital transformation in oncology workflows. Market participants face an increasingly complex environment, marked by emerging disease monitoring tools, shifting supply chain dynamics, and advanced testing modalities.

Market Snapshot: Hematologic Malignancies Testing Market Growth

The global hematologic malignancies testing market grew from USD 3.60 billion in 2024 to USD 3.90 billion in 2025 and is projected to achieve USD 5.69 billion by 2030, reflecting a CAGR of 7.90%. This momentum reflects ongoing innovation in diagnostic technologies as well as increased demand for precision testing in hematologic cancers. Primary drivers include the integration of advanced molecular diagnostics and growing adoption across diverse healthcare settings.

Scope & Segmentation of the Hematologic Malignancies Testing Market

  • Technology: Cytogenetics (including fluorescence in situ hybridization and karyotyping), Flow Cytometry, Immunohistochemistry (liquid-based and tissue-based), Molecular Diagnostics (integrating fluorescence in situ hybridization, next generation sequencing, and polymerase chain reaction)
  • Application: Leukemia, Lymphoma, Multiple Myeloma, Myelodysplastic Syndromes
  • End User: Academic and Research Institutes, Hospitals and Clinics, Reference Laboratories
  • Sample Type: Blood, Bone Marrow
  • Test Mode: Laboratory-Based, Point of Care
  • Regional Coverage: Americas (United States, Canada, Mexico, Brazil, Argentina), Europe, Middle East & Africa (key countries across Western Europe, Middle East, Africa), Asia-Pacific (including China, India, Japan, Australia, South Korea, and others)
  • Market Participants: F. Hoffmann-La Roche AG, Abbott Laboratories, Danaher Corporation, Thermo Fisher Scientific Inc., Becton, Dickinson and Company, Siemens Healthineers AG, QIAGEN N.V., Illumina, Inc., Bio-Rad Laboratories, Inc., Myriad Genetics, Inc.

Key Takeaways for Senior Decision-Makers

  • Integrated diagnostic platforms and advanced analytics are enabling more accurate disease classification, improving both operational efficiency and clinical outcomes for hematologic malignancy patients.
  • Automation and adoption of digital pathology are streamlining laboratory workflows, allowing faster turnaround times and enhanced reproducibility without compromising on diagnostic accuracy.
  • Collaboration between pharmaceutical companies, diagnostic technology firms, and academic research centers is accelerating clinical trial processes and facilitating regulatory compliance for novel assays.
  • The rise of minimally invasive liquid biopsy techniques is transforming patient management by reducing procedural risks and supporting real-time disease monitoring.
  • Reference laboratories are expanding high-complexity offerings, while hospitals and clinics are increasingly adopting point-of-care testing to broaden access to timely diagnostics.
  • Strategic focus on value-based testing protocols and multiplexed workflows helps offset cost pressures, especially in changing regulatory and procurement environments.

Tariff Impact: Navigating U.S. Tariff Policy Shifts

Understanding Supply Chain and Cost Implications

New United States tariffs introduced in 2025 have heightened costs and supply chain uncertainties for key testing reagents and diagnostic equipment. Laboratory decision-makers are pivoting to alternative suppliers and exploring increased domestic sourcing to maintain operational resilience. These tariff-induced adjustments have also prompted a trend toward test menu consolidation and greater adoption of multi-analyte assays, optimizing cost efficiencies while ensuring high-quality diagnostics.

Methodology & Data Sources for the Hematologic Malignancies Testing Market Analysis

This analysis utilizes a mixed methodology framework, combining primary insights from laboratory and industry experts with secondary data from peer-reviewed publications, regulatory filings, and technical white papers. Robust data triangulation and peer review safeguard integrity and accuracy throughout the research process.

Why This Report Matters for Strategic B2B Decisions

  • Gain actionable intelligence on emerging diagnostic innovations and evolving regulatory requirements shaping the hematologic malignancies testing landscape.
  • Understand the operational and strategic responses to external policy shifts, ensuring better preparedness for supply chain or procurement challenges.
  • Benchmark your organization’s strategy against leading industry developments and capitalize on growth opportunities across rapidly expanding regions and clinical segments.

Conclusion

The hematologic malignancies testing market is defined by technological advancement, adaptive business strategies, and a focus on personalized patient care. Leaders who prioritize integrated workflows and data-driven innovation are positioned to capture value in this dynamic sector.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Integration of AI-driven digital pathology platforms for automated blood cancer diagnostics
5.2. Expansion of minimal residual disease monitoring using next-generation sequencing in leukemia management
5.3. Adoption of liquid biopsy assays for non-invasive monitoring of treatment response in lymphoma patients
5.4. Development of point-of-care flow cytometry devices for rapid immunophenotyping in resource-limited settings
5.5. Commercialization of multiplexed genomic panels for simultaneous detection of multiple hematologic malignancy biomarkers
5.6. Regulatory approval pathways accelerating commercialization of CAR T cell therapy companion diagnostics
5.7. Partnerships between pharmaceutical companies and diagnostic labs to co-develop targeted therapy assays in blood cancers
5.8. Implementation of telepathology networks to improve access to expert hematopathology review in underserved regions
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Hematologic Malignancies Testing Market, by Technology
8.1. Introduction
8.2. Cytogenetics
8.2.1. Fluorescence In Situ Hybridization
8.2.2. Karyotyping
8.3. Flow Cytometry
8.4. Immunohistochemistry
8.4.1. Liquid Based
8.4.2. Tissue Based
8.5. Molecular Diagnostics
8.5.1. Fluorescence In Situ Hybridization
8.5.2. Next Generation Sequencing
8.5.3. Polymerase Chain Reaction
9. Hematologic Malignancies Testing Market, by Application
9.1. Introduction
9.2. Leukemia
9.3. Lymphoma
9.4. Multiple Myeloma
9.5. Myelodysplastic Syndromes
10. Hematologic Malignancies Testing Market, by End User
10.1. Introduction
10.2. Academic & Research Institutes
10.3. Hospitals & Clinics
10.4. Reference Laboratories
11. Hematologic Malignancies Testing Market, by Sample Type
11.1. Introduction
11.2. Blood
11.3. Bone Marrow
12. Hematologic Malignancies Testing Market, by Test Mode
12.1. Introduction
12.2. Laboratory Based
12.3. Point Of Care
13. Americas Hematologic Malignancies Testing Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Hematologic Malignancies Testing Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific Hematologic Malignancies Testing Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. F. Hoffmann-La Roche AG
16.3.2. Abbott Laboratories
16.3.3. Danaher Corporation
16.3.4. Thermo Fisher Scientific Inc.
16.3.5. Becton, Dickinson and Company
16.3.6. Siemens Healthineers AG
16.3.7. QIAGEN N.V.
16.3.8. Illumina, Inc.
16.3.9. Bio-Rad Laboratories, Inc.
16.3.10. Myriad Genetics, Inc.
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. HEMATOLOGIC MALIGNANCIES TESTING MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2024 VS 2030 (%)
FIGURE 6. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
FIGURE 8. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 10. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY SAMPLE TYPE, 2024 VS 2030 (%)
FIGURE 12. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY SAMPLE TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TEST MODE, 2024 VS 2030 (%)
FIGURE 14. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TEST MODE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 16. AMERICAS HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 18. UNITED STATES HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. HEMATOLOGIC MALIGNANCIES TESTING MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 24. HEMATOLOGIC MALIGNANCIES TESTING MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 25. HEMATOLOGIC MALIGNANCIES TESTING MARKET: RESEARCHAI
FIGURE 26. HEMATOLOGIC MALIGNANCIES TESTING MARKET: RESEARCHSTATISTICS
FIGURE 27. HEMATOLOGIC MALIGNANCIES TESTING MARKET: RESEARCHCONTACTS
FIGURE 28. HEMATOLOGIC MALIGNANCIES TESTING MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. HEMATOLOGIC MALIGNANCIES TESTING MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY CYTOGENETICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY CYTOGENETICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY FLUORESCENCE IN SITU HYBRIDIZATION, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY FLUORESCENCE IN SITU HYBRIDIZATION, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY KARYOTYPING, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY KARYOTYPING, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY CYTOGENETICS, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY CYTOGENETICS, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY FLOW CYTOMETRY, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY FLOW CYTOMETRY, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY LIQUID BASED, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY LIQUID BASED, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TISSUE BASED, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TISSUE BASED, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY FLUORESCENCE IN SITU HYBRIDIZATION, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY FLUORESCENCE IN SITU HYBRIDIZATION, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY LEUKEMIA, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY LEUKEMIA, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY LYMPHOMA, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY LYMPHOMA, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY MULTIPLE MYELOMA, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY MULTIPLE MYELOMA, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY MYELODYSPLASTIC SYNDROMES, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY MYELODYSPLASTIC SYNDROMES, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY REFERENCE LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY REFERENCE LABORATORIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY SAMPLE TYPE, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY BLOOD, BY REGION, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY BLOOD, BY REGION, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY BONE MARROW, BY REGION, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY BONE MARROW, BY REGION, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TEST MODE, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TEST MODE, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY LABORATORY BASED, BY REGION, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY LABORATORY BASED, BY REGION, 2025-2030 (USD MILLION)
TABLE 67. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY POINT OF CARE, BY REGION, 2018-2024 (USD MILLION)
TABLE 68. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY POINT OF CARE, BY REGION, 2025-2030 (USD MILLION)
TABLE 69. AMERICAS HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 70. AMERICAS HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 71. AMERICAS HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY CYTOGENETICS, 2018-2024 (USD MILLION)
TABLE 72. AMERICAS HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY CYTOGENETICS, 2025-2030 (USD MILLION)
TABLE 73. AMERICAS HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2024 (USD MILLION)
TABLE 74. AMERICAS HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2025-2030 (USD MILLION)
TABLE 75. AMERICAS HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2024 (USD MILLION)
TABLE 76. AMERICAS HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2025-2030 (USD MILLION)
TABLE 77. AMERICAS HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 78. AMERICAS HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 79. AMERICAS HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 80. AMERICAS HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 81. AMERICAS HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
TABLE 82. AMERICAS HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY SAMPLE TYPE, 2025-2030 (USD MILLION)
TABLE 83. AMERICAS HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TEST MODE, 2018-2024 (USD MILLION)
TABLE 84. AMERICAS HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TEST MODE, 2025-2030 (USD MILLION)
TABLE 85. AMERICAS HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 86. AMERICAS HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 87. UNITED STATES HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 88. UNITED STATES HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 89. UNITED STATES HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY CYTOGENETICS, 2018-2024 (USD MILLION)
TABLE 90. UNITED STATES HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY CYTOGENETICS, 2025-2030 (USD MILLION)
TABLE 91. UNITED STATES HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2024 (USD MILLION)
TABLE 92. UNITED STATES HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2025-2030 (USD MILLION)
TABLE 93. UNITED STATES HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2024 (USD MILLION)
TABLE 94. UNITED STATES HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2025-2030 (USD MILLION)
TABLE 95. UNITED STATES HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 96. UNITED STATES HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 97. UNITED STATES HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 98. UNITED STATES HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 99. UNITED STATES HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
TABLE 100. UNITED STATES HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY SAMPLE TYPE, 2025-2030 (USD MILLION)
TABLE 101. UNITED STATES HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TEST MODE, 2018-2024 (USD MILLION)
TABLE 102. UNITED STATES HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TEST MODE, 2025-2030 (USD MILLION)
TABLE 103. UNITED STATES HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 104. UNITED STATES HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 105. CANADA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 106. CANADA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 107. CANADA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY CYTOGENETICS, 2018-2024 (USD MILLION)
TABLE 108. CANADA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY CYTOGENETICS, 2025-2030 (USD MILLION)
TABLE 109. CANADA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2024 (USD MILLION)
TABLE 110. CANADA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2025-2030 (USD MILLION)
TABLE 111. CANADA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2024 (USD MILLION)
TABLE 112. CANADA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2025-2030 (USD MILLION)
TABLE 113. CANADA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 114. CANADA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 115. CANADA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 116. CANADA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 117. CANADA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
TABLE 118. CANADA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY SAMPLE TYPE, 2025-2030 (USD MILLION)
TABLE 119. CANADA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TEST MODE, 2018-2024 (USD MILLION)
TABLE 120. CANADA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TEST MODE, 2025-2030 (USD MILLION)
TABLE 121. MEXICO HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 122. MEXICO HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 123. MEXICO HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY CYTOGENETICS, 2018-2024 (USD MILLION)
TABLE 124. MEXICO HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY CYTOGENETICS, 2025-2030 (USD MILLION)
TABLE 125. MEXICO HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2024 (USD MILLION)
TABLE 126. MEXICO HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2025-2030 (USD MILLION)
TABLE 127. MEXICO HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2024 (USD MILLION)
TABLE 128. MEXICO HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2025-2030 (USD MILLION)
TABLE 129. MEXICO HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 130. MEXICO HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 131. MEXICO HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 132. MEXICO HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 133. MEXICO HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
TABLE 134. MEXICO HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY SAMPLE TYPE, 2025-2030 (USD MILLION)
TABLE 135. MEXICO HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TEST MODE, 2018-2024 (USD MILLION)
TABLE 136. MEXICO HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TEST MODE, 2025-2030 (USD MILLION)
TABLE 137. BRAZIL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 138. BRAZIL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 139. BRAZIL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY CYTOGENETICS, 2018-2024 (USD MILLION)
TABLE 140. BRAZIL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY CYTOGENETICS, 2025-2030 (USD MILLION)
TABLE 141. BRAZIL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2024 (USD MILLION)
TABLE 142. BRAZIL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2025-2030 (USD MILLION)
TABLE 143. BRAZIL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2024 (USD MILLION)
TABLE 144. BRAZIL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2025-2030 (USD MILLION)
TABLE 145. BRAZIL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 146. BRAZIL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 147. BRAZIL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 148. BRAZIL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 149. BRAZIL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
TABLE 150. BRAZIL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY SAMPLE TYPE, 2025-2030 (USD MILLION)
TABLE 151. BRAZIL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TEST MODE, 2018-2024 (USD MILLION)
TABLE 152. BRAZIL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TEST MODE, 2025-2030 (USD MILLION)
TABLE 153. ARGENTINA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 154. ARGENTINA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 155. ARGENTINA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY CYTOGENETICS, 2018-2024 (USD MILLION)
TABLE 156. ARGENTINA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY CYTOGENETICS, 2025-2030 (USD MILLION)
TABLE 157. ARGENTINA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2024 (USD MILLION)
TABLE 158. ARGENTINA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2025-2030 (USD MILLION)
TABLE 159. ARGENTINA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2024 (USD MILLION)
TABLE 160. ARGENTINA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2025-2030 (USD MILLION)
TABLE 161. ARGENTINA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 162. ARGENTINA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 163. ARGENTINA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 164. ARGENTINA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 165. ARGENTINA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
TABLE 166. ARGENTINA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY SAMPLE TYPE, 2025-2030 (USD MILLION)
TABLE 167. ARGENTINA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TEST MODE, 2018-2024 (USD MILLION)
TABLE 168. ARGENTINA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TEST MODE, 2025-2030 (USD MILLION)
TABLE 169. EUROPE, MIDDLE EAST & AFRICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 170. EUROPE, MIDDLE EAST & AFRICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 171. EUROPE, MIDDLE EAST & AFRICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY CYTOGENETICS, 2018-2024 (USD MILLION)
TABLE 172. EUROPE, MIDDLE EAST & AFRICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY CYTOGENETICS, 2025-2030 (USD MILLION)
TABLE 173. EUROPE, MIDDLE EAST & AFRICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2024 (USD MILLION)
TABLE 174. EUROPE, MIDDLE EAST & AFRICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2025-2030 (USD MILLION)
TABLE 175. EUROPE, MIDDLE EAST & AFRICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2024 (USD MILLION)
TABLE 176. EUROPE, MIDDLE EAST & AFRICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2025-2030 (USD MILLION)
TABLE 177. EUROPE, MIDDLE EAST & AFRICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 178. EUROPE, MIDDLE EAST & AFRICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 179. EUROPE, MIDDLE EAST & AFRICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 180. EUROPE, MIDDLE EAST & AFRICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 181. EUROPE, MIDDLE EAST & AFRICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
TABLE 182. EUROPE, MIDDLE EAST & AFRICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY SAMPLE TYPE, 2025-2030 (USD MILLION)
TABLE 183. EUROPE, MIDDLE EAST & AFRICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TEST MODE, 2018-2024 (USD MILLION)
TABLE 184. EUROPE, MIDDLE EAST & AFRICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TEST MODE, 2025-2030 (USD MILLION)
TABLE 185. EUROPE, MIDDLE EAST & AFRICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 186. EUROPE, MIDDLE EAST & AFRICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 187. UNITED KINGDOM HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 188. UNITED KINGDOM HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 189. UNITED KINGDOM HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY CYTOGENETICS, 2018-2024 (USD MILLION)
TABLE 190. UNITED KINGDOM HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY CYTOGENETICS, 2025-2030 (USD MILLION)
TABLE 191. UNITED KINGDOM HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2024 (USD MILLION)
TABLE 192. UNITED KINGDOM HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2025-2030 (USD MILLION)
TABLE 193. UNITED KINGDOM HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2024 (USD MILLION)
TABLE 194. UNITED KINGDOM HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2025-2030 (USD MILLION)
TABLE 195. UNITED KINGDOM HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 196. UNITED KINGDOM HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 197. UNITED KINGDOM HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 198. UNITED KINGDOM HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 199. UNITED KINGDOM HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
TABLE 200. UNITED KINGDOM HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY SAMPLE TYPE, 2025-2030 (USD MILLION)
TABLE 201. UNITED KINGDOM HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TEST MODE, 2018-2024 (USD MILLION)
TABLE 202. UNITED KINGDOM HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TEST MODE, 2025-2030 (USD MILLION)
TABLE 203. GERMANY HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 204. GERMANY HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 205. GERMANY HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY CYTOGENETICS, 2018-2024 (USD MILLION)
TABLE 206. GERMANY HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY CYTOGENETICS, 2025-2030 (USD MILLION)
TABLE 207. GERMANY HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2024 (USD MILLION)
TABLE 208. GERMANY HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2025-2030 (USD MILLION)
TABLE 209. GERMANY HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2024 (USD MILLION)
TABLE 210. GERMANY HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2025-2030 (USD MILLION)
TABLE 211. GERMANY HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 212. GERMANY HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 213. GERMANY HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 214. GERMANY HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 215. GERMANY HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
TABLE 216. GERMANY HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY SAMPLE TYPE, 2025-2030 (USD MILLION)
TABLE 217. GERMANY HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TEST MODE, 2018-2024 (USD MILLION)
TABLE 218. GERMANY HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TEST MODE, 2025-2030 (USD MILLION)
TABLE 219. FRANCE HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 220. FRANCE HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 221. FRANCE HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY CYTOGENETICS, 2018-2024 (USD MILLION)
TABLE 222. FRANCE HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY CYTOGENETICS, 2025-2030 (USD MILLION)
TABLE 223. FRANCE HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2024 (USD MILLION)
TABLE 224. FRANCE HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2025-2030 (USD MILLION)
TABLE 225. FRANCE HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2024 (USD MILLION)
TABLE 226. FRANCE HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2025-2030 (USD MILLION)
TABLE 227. FRANCE HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 228. FRANCE HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 229. FRANCE HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 230. FRANCE HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 231. FRANCE HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
TABLE 232. FRANCE HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY SAMPLE TYPE, 2025-2030 (USD MILLION)
TABLE 233. FRANCE HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TEST MODE, 2018-2024 (USD MILLION)
TABLE 234. FRANCE HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TEST MODE, 2025-2030 (USD MILLION)
TABLE 235. RUSSIA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 236. RUSSIA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 237. RUSSIA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY CYTOGENETICS, 2018-2024 (USD MILLION)
TABLE 238. RUSSIA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY CYTOGENETICS, 2025-2030 (USD MILLION)
TABLE 239. RUSSIA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2024 (USD MILLION)
TABLE 240. RUSSIA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2025-2030 (USD MILLION)
TABLE 241. RUSSIA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2024 (USD MILLION)
TABLE 242. RUSSIA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2025-2030 (USD MILLION)
TABLE 243. RUSSIA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 244. RUSSIA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 245. RUSSIA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 246. RUSSIA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 247. RUSSIA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
TABLE 248. RUSSIA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY SAMPLE TYPE, 2025-2030 (USD MILLION)
TABLE 249. RUSSIA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TEST MODE, 2018-2024 (USD MILLION)
TABLE 250. RUSSIA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TEST MODE, 2025-2030 (USD MILLION)
TABLE 251. ITALY HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 252. ITALY HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 253. ITALY HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY CYTOGENETICS, 2018-2024 (USD MILLION)
TABLE 254. ITALY HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY CYTOGENETICS, 2025-2030 (USD MILLION)
TABLE 255. ITALY HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2024 (USD MILLION)
TABLE 256. ITALY HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2025-2030 (USD MILLION)
TABLE 257. ITALY HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2024 (USD MILLION)
TABLE 258. ITALY HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2025-2030 (USD MILLION)
TABLE 259. ITALY HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 260. ITALY HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 261. ITALY HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 262. ITALY HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 263. ITALY HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
TABLE 264. ITALY HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY SAMPLE TYPE, 2025-2030 (USD MILLION)
TABLE 265. ITALY HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TEST MODE, 2018-2024 (USD MILLION)
TABLE 266. ITALY HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TEST MODE, 2025-2030 (USD MILLION)
TABLE 267. SPAIN HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 268. SPAIN HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 269. SPAIN HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY CYTOGENETICS, 2018-2024 (USD MILLION)
TABLE 270. SPAIN HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY CYTOGENETICS, 2025-2030 (USD MILLION)
TABLE 271. SPAIN HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2024 (USD MILLION)
TABLE 272. SPAIN HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2025-2030 (USD MILLION)
TABLE 273. SPAIN HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2024 (USD MILLION)
TABLE 274. SPAIN HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2025-2030 (USD MILLION)
TABLE 275. SPAIN HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 276. SPAIN HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 277. SPAIN HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 278. SPAIN HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 279. SPAIN HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
TABLE 280. SPAIN HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY SAMPLE TYPE, 2025-2030 (USD MILLION)
TABLE 281. SPAIN HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TEST MODE, 2018-2024 (USD MILLION)
TABLE 282. SPAIN HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TEST MODE, 2025-2030 (USD MILLION)
TABLE 283. UNITED ARAB EMIRATES HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 284. UNITED ARAB EMIRATES HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 285. UNITED ARAB EMIRATES HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY CYTOGENETICS, 2018-2024 (USD MILLION)
TABLE 286. UNITED ARAB EMIRATES HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY CYTOGENETICS, 2025-2030 (USD MILLION)
TABLE 287. UNITED ARAB EMIRATES HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2024 (USD MILLION)
TABLE 288. UNITED ARAB EMIRATES HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2025-2030 (USD MILLION)
TABLE 289. UNITED ARAB EMIRATES HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2024 (USD MILLION)
TABLE 290. UNITED ARAB EMIRATES HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2025-2030 (USD MILLION)
TABLE 291. UNITED ARAB EMIRATES HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 292. UNITED ARAB EMIRATES HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 293. UNITED ARAB EMIRATES HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 294. UNITED ARAB EMIRATES HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 295. UNITED ARAB EMIRATES HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
TABLE 296. UNITED ARAB EMIRATES HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY SAMPLE TYPE, 2025-2030 (USD MILLION)
TABLE 297. UNITED ARAB EMIRATES HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TEST MODE, 2018-2024 (USD MILLION)
T

Samples

Loading
LOADING...

Companies Mentioned

The major companies profiled in this Hematologic Malignancies Testing market report include:
  • F. Hoffmann-La Roche AG
  • Abbott Laboratories
  • Danaher Corporation
  • Thermo Fisher Scientific Inc.
  • Becton, Dickinson and Company
  • Siemens Healthineers AG
  • QIAGEN N.V.
  • Illumina, Inc.
  • Bio-Rad Laboratories, Inc.
  • Myriad Genetics, Inc.

Table Information

Report AttributeDetails
No. of Pages197
PublishedAugust 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 3.9 Billion
Forecasted Market Value ( USD ) by 2030 $ 5.69 Billion
Compound Annual Growth Rate7.9%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Hematologic Malignancies Testing Global Market Report 2025 - Product Image

Hematologic Malignancies Testing Global Market Report 2025

  • Report
  • 175 Pages
  • Global
From
Precision Immuno-Oncology Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F - Product Image

Precision Immuno-Oncology Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F

  • Report
  • 180 Pages
  • Global
From
Europe Hematologic Malignancies Testing Market, By Country, Competition, Forecast and Opportunities, 2020-2030F - Product Image

Europe Hematologic Malignancies Testing Market, By Country, Competition, Forecast and Opportunities, 2020-2030F

  • Report
  • 133 Pages
  • Europe
From
Europe Hematologic Malignancies Testing Market: Focus on Product, Platform, Disease, End User, and Country - Analysis and Forecast, 2024-2033 - Product Image

Europe Hematologic Malignancies Testing Market: Focus on Product, Platform, Disease, End User, and Country - Analysis and Forecast, 2024-2033

  • Report
  • 100 Pages
  • Europe
From
Hematologic Malignancies Detection Market Report 2025 - Product Image

Hematologic Malignancies Detection Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.